The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
Số trang: 7
Loại file: pdf
Dung lượng: 1.16 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or CalmetteGuerin (BCG) for no more than one year after transurethral resection of bladder tumor (TURBT), there is no consensus on the optimal duration of chemotherapy.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Non-muscle-invasive Bladder cancer Intravesical chemotherapy Tumor recurrence Operating characteristic curveTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 172 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 94 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 44 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0